GlobeNewswire

Orange Polska and Orange Belgium Partner with Salesforce and Vlocity to Strengthen Their Digital Transformation

Dela

WARSAW, Poland and BRUSSELS, Belgium and SAN FRANCISCO, March 28, 2018 (GLOBE NEWSWIRE) -- Orange Polska and Orange Belgium announced today that they signed an agreement with Salesforce, the global leader in CRM, and Vlocity, a leading industry cloud company. Salesforce and Vlocity will help Orange achieve business agility faster and reduce time to market by leveraging cloud-based solutions across Orange's digital and assisted channels.

Given today's digital landscape, it's become imperative for Orange to strengthen its position in mobile and convergence markets with a customer-centric focus. Thanks to the expertise of Salesforce and Vlocity, Orange can further improve the quality of its customer experience by introducing a robust omnichannel experience for its customers. In addition, Orange sales teams and channel partners will be able to sell new innovative products and services smarter, helping them go the extra mile for Orange customers.

Orange Polska takes a significant step in its digital transformation

"Orange Polska is moving a step further in its digital transformation. Having reached a significant level of consolidation of its digital and sales channels, Orange Polska now targets to offer a differentiating customer experience." said Jean-François Fallacher, CEO of Orange Polska. "We choose Vlocity and Salesforce for their deployment speed but also for their advanced products and journey management capabilities. This partnership will enable us to meet our customers' expectations for simple, transparent, easy-to-use and easy-to-manage offers. Innovation and customer experience are significant cornerstones of the Orange strategy."

Orange Belgium continues to digitalize the Orange customer journey

"Orange Belgium continues its digital transformation. Next to renewing certain levels of our order management, we will now start strengthening our CRM capabilities and unifying our digital channels. In this perspective, we partnered up with Vlocity and Salesforce," said Michaël Trabbia, CEO of Orange Belgium. "We chose Salesforce and Vlocity because they demonstrate advantages on multiple fronts, including speed to deployment, accelerated time-to-market and streamlined service delivery. This collaboration will indeed enable us to further digitize our customer journey and to be even more relevant for our customers, who remain at the heart of the Orange Belgium strategy."

Salesforce and Vlocity empower Orange to fully engage in digital transformation

"By embracing the cloud, Orange has taken an important step in its core mission to achieve outstanding customer connectivity and make its services easier to access and sell," said Jo Buvens, Country Manager Salesforce Belgium and Luxembourg. "We're thrilled to be working with Vlocity on this important project. By leveraging Vlocity's industry specific cloud solutions and omnichannel applications, Orange can now fully engage in its digital transformation."

"We're incredibly excited about this opportunity to join forces with Salesforce to provide Orange with the industry-focused digital software that they need to transform the way they do business," said Dominic Dinardo, EVP and Managing Director EMEA, Vlocity. "We're thrilled to be selected as Orange's digital transformation technology and look forward to helping Orange capture more value from the cloud, reach more customers, sell smarter and sell more efficiently."

Vlocity Communications takes advantage of the omnichannel capabilities of Salesforce Service Cloud and includes comprehensive Enterprise Product Catalog, CPQ (Configure-Price-Quote), Contract Management, Retail Clienteling and Order Management functionality, and a comprehensive library of pre-built sales, service and billing inquiry management processes. Engineered specifically for communications service providers, Vlocity Communications conforms to TM Forum industry standards, and integrates flexibly with third-party systems through pre-built APIs and web services. For more information on Vlocity Communications, please click here.

Salesforce and others are among the trademarks of salesforce.com , inc.

About Vlocity
Vlocity, a Forbes Cloud 100 company and strategic Salesforce ISV, delivers industry-specific cloud and mobile software that embed digital, omnichannel processes for customer-centric industries. Built in partnership with Salesforce, the world's #1 CRM company, Vlocity is one of Salesforce's fastest growing partners. Vlocity Industry Cloud Apps embed industry-specific functionality, best practices and business processes for the Communications & Media, Insurance & Financial Services, Health Insurance, Energy and Public Sector industries. Vlocity enables companies to achieve faster business agility and time to value from the cloud across digital and traditional channels. Learn more at www.vlocity.com and follow us at @vlocity.

About Orange Polska
Orange Polska is Poland's leading telecommunication provider, operating in all segments of the telecom market. We have the largest technical infrastructure in Poland, enabling us to provide services and convergent offers based on cutting-edge technologies, including fiber internet, 4G/LTE mobile data transmission and 4K TV. We invest intensely in both mobile and fixed networks, our ambition is to cover more than 5 million households in Poland with fiber by the end of 2020. Our mobile 4G/LTE network now covers almost the entire population of Poland. Orange Polska is one of the most socially committed companies in the country. The programs of Orange Foundation counteract digital exclusion and develop digital skills. 
Orange Polska is listed on the Warsaw Stock Exchange. We are part of the global Orange Group.

More information on: https://www.orange.pl; follow us on Twitter: @ Orange_Polska

About Orange Belgium
Orange Belgium is one of the leading telecommunication operators on the Belgian market, with over 3 million customers, and in Luxembourg through its subsidiary Orange Communications Luxembourg. As a convergent actor, we provide mobile telecommunication services, internet and TV to private clients, as well as innovative mobile and fixed line services to businesses. Our high-performance mobile network supports 2G, 3G, 4G and 4G+ technology and is the subject of ongoing investments.  Orange Belgium is a subsidiary of the Orange Group, one of the leading European and African operators for mobile telephony and internet access, as well as one of the world leaders for telecommunication services to enterprises. Orange Belgium is listed on the Brussels Stock Exchange (OBEL). More information on: corporate.orange.bewww.orange.be  or follow us on Twitter : @pressOrangeBe.

Press Contacts

Orange Polska
Wojciech Jabczynski - wojciech.jabczynski@orange.com

Orange Belgium
Annelore Marynissen - annelore.marynissen@orange.com  -  +32 (0) 479 01 60 58
Jean-Pascal Bouillon - jean-pascal.bouillon@orange.com  -  +32 (0) 473 94 87 31
press@orange.be

Contact investors
Siddy Jobe - ir@orange.be - +32(0)2 745 80 92

Vlocity
Bhava Communications for Vlocity
Rachel Austin
vlocity@bhavacom.com
979-324-7905




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Vlocity via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum